Proteolytic processing of human coagulation factor IX by plasmin

Blood

Volumn 95, Issue 3, 2000, Pages 943-951

  Samis, John A ^a   Ramsey, Gillian D ^a   Walker, John B ^a   Nesheim, Michael E ^a   Giles, Alan R ^a,b  

^a QUEEN S UNIVERSITY   (Canada)

^b HEART AND STROKE FOUNDATION OF CANADA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBENZAMIDINE; ANTITHROMBIN; BLOOD CLOTTING FACTOR 9; PLASMIN; PROCOAGULANT;

AMINO TERMINAL SEQUENCE; ARTICLE; BLOOD CLOT LYSIS; BLOOD CLOTTING; CONTROLLED STUDY; DOWN REGULATION; HUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION;

EID: 0034141459     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.3.943.003k34_943_951     Document Type: Article

References (57)

1. Kalafatis M, Egan JO, van't Veer C, Cawthern KM, Mann KG. The regulation of clotting factors. Crit Rev Eukaryot Gene Expr. 1997;7:241.
2. Broze GJ Jr. Tissue factor pathway inhibitor and the revised theory of coagulation. Ann Rev Med. 1995;46:103.
3. Carmeliet P, Collen D. Gene targeting and gene transfer studies of the biological role of the plasminogen/plasmin system. Thromb Haemost. 1995;74:429.
4. Collen D, Lijnen HR. Fibrin-specific fibrinolysis. Ann N Y Acad Sci. 1992;667:259.
5. Perler BA. Hypercoagulability and the hypercoagulability syndromes. AJR Am J Roentgenol. 1995;164:559.
6. Carmeliet P, Collen D. Genetic analysis of the plasminogen and coagulation system in mice. Haemostasis. 1996;26(suppl):132.
7. Hatton MW, Southward SM, Ross-Ouellet B, DeReske M, Blajchman MA, Richardson M. An increased uptake of prothrombin, AT, and fibrinogen by the rabbit balloon-deendothelialized aorta surface in vivo is maintained until reendothelialization is complete. Arterioscl Thromb Vasc Biol. 1996;16:1147.
8. van Wersch JW, Tjwa MK. Coagulation/fibrinolysis balance and lung cancer. Haemostasis. 1991; 21:117.
9. Carmassi F, Morale M, Puccetti R, et al. Coagulation and fibrinolytic system impairment in insulin dependent diabetes mellitus. Thromb Res. 1992; 67:643.
10. Bick RL. Disseminated intravascular coagulation: pathophysiological mechanisms and manifestations. Semin Thromb Hemost. 1998;24:3.
11. Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem. 1995;270: 14, 477.
12. Osterud B, Laake K, Prydz H. The activation of human factor IX. Thromb Diath Haemorrh. 1975; 33:553.
13. Laake K, Osterud B. Activation of purified plasma factor VII by human plasmin, plasma kallikrein, and activated components of the human intrinsic blood coagulation system. Thromb Res. 1974;5: 759.
14. Ewald GA, Eisenberg PR. Plasmin-mediated activation of the contact system in response to pharmacological thrombolysis. Circulation. 1995; 91:28.
15. Lee CD, Mann KG. Activation/inactivation of human factor V by plasmin. Blood. 1989;73:185.
16. Rick ME, Krizek DM. Platelets modulate the proteolysis of factor VIII:C protein by plasmin. Blood. 1986;67:1649.
17. Giles AR, Mann KG, Nesheim ME. A combination of factor Xa and phosphatidylcholine-phosphatidylserine vesicles bypasses factor VIII in vivo. Br J Haematol. 1988;69:491.
18. Hoogendoorn H, Nesheim ME, Giles AR. A qualitative and quantitative analysis of the activation and inactivation of protein C in vivo in a primate model. Blood. 1990;75:2164.
19. Giles AR, Nesheim ME, Herring SW, Hoogendoorn H, Stump DC, Heldebrant CM. The fibrinolytic potential of the normal primate following the generation of thrombin in vivo. Thromb Haemost. 1990;63:476.
20. Giles AR, Nesheim ME, Mann KG. Studies of factors V and VIII:C in an animal model of disseminated intravascular coagulation. J Clin Invest. 1984;74:2219.
21. Hoogendoorn H, Weitz JI, Giles AR. Evidence for the generation of elastase activity in a primate model of disseminated intravascular coagulation (DIC) [abstract]. Thromb Haemost. 1993;69:1127.
22. Fujikawa K, Legaz ME, Kato H, Davie EW. The mechanism of activation of bovine factor IX (Christmas factor) by bovine XIa. Biochemistry. 1974;13:4508.
23. Osterud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc Natl Acad Sci U S A. 1977;74:5260.
24. Thompson AR. Radioimmunoassay of factor IX in the hemophilias. Methods Hematol. 1982;5:122.
25. Anson DS, Choo KH, Rees DJG, et al. The gene structure of human anti-haemophilic factor IX. EMBO J 1984;3:1053.
26. Lenting PJ, ter Matt H, Clijsters PPFM, Donath M-JSH, van Mourik JA, Mertens K. Cleavage at arginine 145 in human blood coagulation factor IX converts the zymogen into a factor VIII binding enzyme. J Biol Chem. 1995;270:14,884.
27. Lawson JH, Mann KG. Cooperative activation of human factor IX by the human extrinsic pathway of blood coagulation. J Biol Chem. 1991;266:11,317.
28. Brandstetter H, Bauer M, Huber R, Lollar P, Bode W. X-ray structure of clotting factor IXa: active site and module structure to Xase activity and hemophilia B. Proc Natl Acad Sci U S A. 1995;92: 9796.
29. Bajaj SP, Rapaport SI, Maki SL, Brown SF. A procedure for the isolation of human protein C and protein S as by products of the purification of factors VII, IX, X and prothrombin. Prep Biochem. 1983;13:191.
30. Lundblad RL, Kingdon HS, Mann KG. Thrombin. In: Lorand L, ed. Methods in Enzymology. New York, NY: Academic; 1976:156.
31. Fujikawa K, Legaz ME, Davie EW. Bovine factor X (Stuart Factor). Mechanism of activation by a protein from Russell's viper venom. Biochemistry. 1972;11:4892.
32. Barenholz Y, Gibbs D, Litman BJ, Goll J, Thompson D, Carlson FD. A simple method for the preparation of homogeneous phospholipid vesicles. Biochem J. 1977;16:2806.
33. Gomori G. A modification of the colorimetric phosphorous determination for use with the photoelectric colorimeter. J Lab Clin Med. 1942;27:955.
34. Castellino FJ, Powell JR. Human plasminogen. Methods Enzymol. 1981;80:365.
35. Bajzar L, Fredenburgh JC, Nesheim ME. The activated protein C-mediated enhancement of tissue-type plasminogen activator-induced fibrinolysis in a cell-free system. J Biol Chem. 1990;265: 16,948.
36. Nesheim ME, Prendergast FG, Mann KG. Interactions of a fluorescent active-site-directed inhibitor of thrombin: dansylarginine N-(3-ethyl-1,5-pentanediyl) amide. Biochemistry. 1979;18:996.
37. Hoogendoorn H, Cerskus A, Ofosu F, Blajchman M, Hirsh J. Preparation and partial characterization of human plasma depleted of AT-III by heparin-sepharose affinity chromatography. Thromb Res. 1980;20:77.
38. Samis JA, Kam EK, Nesheim ME, Giles AR. Neutrophil elastase cleavage of human factor IX generates an activated factor IX-like product devoid of coagulant function. Blood 1998;92:1287.
39. Neville DM. Molecular weight determination of protein-dodecylsulfate complexes by gel electrophoresis in a discontinuous buffer. J Biol Chem. 1971;246:6328.
40. Lin S-W, Lin C-N, Hamaguchi N, Smith KJ, Shen M-C. Characterization of a factor IX variant with a glycine 207 to glutamic acid mutation. Blood. 1994;84:1866.
41. Astermark J, Hogg PJ, Bjork I, Stenflo J. Effects of γ-carboxyglutamic acid and epidermal growth factor-like modules of factor IX on factor X activation. J Biol Chem. 1992;267:3249.
42. 92 by His in the second epidermal growth factor-like domain results in defective interaction of factors VIIIa/X. J Biol Chem. 1993;268:24,041.
43. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A. 1979;76:4350.
44. Ploplis VA, Carmeliet P, Vazirzadeh S, et al. Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice. Circulation. 1995;92:2585.
45. Cui J, O'Shea KS, Purkayastha A, Saunders TL, Ginsburg D. Fatal haemorrhage and incomplete block to embryogenesis in mice lacking factor V Nature. 1996;384:66.
46. Zoller B, Svensson PJ, He X, Dahlback B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest. 1994;94:2521.
47. Nichols WC, Terry VH, Wheatley MA, et al. ERGIC-53 gene structure and mutation analysis in 19 combined factors V and VIII deficient families. Blood. 1999;93:2261.
48. Giles AR. Disseminated intravascular coagulation. In: Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD, eds. Haemostasis and Thrombosis. Vol 2. New York, NY: Churchill Livingstone: 1994:969.
49. Taylor FB Jr, Hoogendoorn H, Chang AC, et al. Anticoagulant and fibrinolytic activities are promoted, not retarded, in vivo after thrombin generation in the presence of a monoclonal antibody that inhibits activation of protein C. Blood. 1992; 79:1720.
50. Pfitzner SA, Dempfle CE, Matsuda M, Heene DL. Fibrin detected in plasma of patients with disseminated intravascular coagulation by fibrin-specific antibodies consists primarily of high molecular weight factor XIIIa-crosslinked and plasmin-modified complexes partially containing fibrinopeptide A. Thromb Haemost. 1997;78: 1069.
51. Takahashi H, Hanano M, Takizawa S, Tatewaki W, Shibata A. Plasmin-alpha-2-plasmin inhibitor complex in plasma of patients with disseminated intravascular coagulation. Am J Hematol. 1988; 28:162.
52. Weinstein MJ, Doolittle RF. Differential specificities of the thrombin, plasmin and trypsin with regard to synthetic and natural substrates and inhibitors. Biochim Biophys Acta. 1972;258:577
53. Thompson AR. Structure and biology of factor IX. In: Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ. eds. Hematology: Basic Principles and Practices. New York, NY: Churchill Livingstone; 1991:1308.
54. Kisiel W, Smith KJ, McMullen BA. Proteolytic inactivation of blood coagulation factor IX by thrombin. Blood 1985;66:1302.
55. Burn BJ, Edgington TS, Fair DS. Molecular interactions of the intrinsic activation complex of coagulation: binding of native and activated human factors IX and X to defined phospholipid vesicles. Biochim Biophys Acta. 1987;923:176.
56. Aoki N, Harpel P. Inhibitors of the fibrinolytic system. Semin Thromb Hemost. 1984;10:24.
57. Lijnen HR, Van Hoef B, Matsuo O, Collen D. On the molecular interactions between plasminogen-staphylokinase, alpha-2-antiplasmin and fibrin. Biochim Biophys Acta. 1992;1118:144.